Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38301187

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2024 Apr 10
First author
Ganz PA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Gland Surg. 2025 Feb 28;14(2):257-262. doi: 10.21037/gs-24-467.
    note
    Source null
    related pmid
    40115853
    relationship
    Comment in

Authors and identifiers

  1. name
    Ganz PA
    type
    Author
  2. name
    Bandos H
    type
    Author
  3. name
    Španić T
    type
    Author
  4. name
    Friedman S
    type
    Author
  5. name
    Müller V
    type
    Author
  6. name
    Kuemmel S
    type
    Author
  7. name
    Delaloge S
    type
    Author
  8. name
    Brain E
    type
    Author
  9. name
    Toi M
    type
    Author
  10. name
    Yamauchi H
    type
    Author
  11. name
    de Dueñas EM
    type
    Author
  12. name
    Armstrong A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ganz PA
    type
    Author
  2. name
    Bandos H
    type
    Author
  3. name
    Španić T
    type
    Author
  4. name
    Friedman S
    type
    Author
  5. name
    Müller V
    type
    Author
  6. name
    Kuemmel S
    type
    Author
  7. name
    Delaloge S
    type
    Author
  8. name
    Brain E
    type
    Author
  9. name
    Toi M
    type
    Author
  10. name
    Yamauchi H
    type
    Author
  11. name
    de Dueñas EM
    type
    Author
  12. name
    Armstrong A
    type
    Author
bibliography ids
  1. nci-bib-2ad4fe22a40f55fed9cf1b8e
book metadata
content sha256
70b8aad6e638a2ee270bd71d8dbc44e0de2bf22c7266de94f32f3f1c610b7288
document type
citation
dois
  1. 10.1200/JCO.23.01214
electronic publication date
display
2024 Feb 1
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38301187
immutable id
pubmed:38301187@70b8aad6e638a2ee270bd71d8dbc44e0de2bf22c7266de94f32f3f1c610b7288
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
11
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1288-1300
volume
42
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Gland Surg. 2025 Feb 28;14(2):257-262. doi: 10.21037/gs-24-467.
    note
    Source null
    related pmid
    40115853
    relationship
    Comment in
outcomes validated
false
pmid
38301187
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
4fdc01e02579ee16c367b30164f74d40a5a185e2e6508cc3e3d83112b34c5260
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Apr 10
precision
day
year
2024
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38301187/
title
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Preserved source evidence · Not medical advice